Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
To study the predictors contribute to the progression of COPD by follow-up of patients with early COPD and analyze their changes in bioactive molecular, exhaled gas, CT image, lung function, patient's symptoms and life quality.
Detailed description
A research found that nearly 40% of patients with chronic respiratory symptoms who showed significant airway inflammation (airway wall thickening and/or lung structure destruction (emphysema) on chest CT had advanced COPD within 5 years, although their current lung function failed to meet diagnostic criteria for COPD. Current spirometry-based diagnostic methods are not the best predictors of COPD progression and death. CT indicated emphysema and airway inflammation were recognized as better predictors of disease progression and mortality. Based on a large cohort study, some scholars proposed the concept of early COPD, focusing on people under the age of 50, smoking for more than 10 pack years, having one of the manifestations of early airflow limitation, abnormal chest CT, and rapid decline of FEV1, to study the mechanism of disease progression and early intervention methods.\[4\] In this study, we enroll participants with early COPD symptoms, to detect the progression of COPD with 3 years of follow-up. The predictors of disease progression and variants of bioactive molecular were analyzed, so as to clarify the progressive mechanism of COPD.
Interventions
None listed
Sponsors
Peking University Third Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* 1\. \<60 years old; 2\. Smoking ≥ 10 pack years. 3\. With any of the following anomalies: a. Post-bronchodilator FEV1/FVC\< 0.7. b. CT image abnormalities: emphysema, air trapping or bronchial wall thickening; c.Rapid decrease of FEV1 (\>60 ml/yr).
Exclusion criteria
* 1\. With other known chronic lung diseases, including bronchiectasis, interstitial pulmonary disease, tuberculosis, and pulmonary vascular disease (CTEPH). 2\. With severe pleural disease and/or lesions of the sternum or ribs. 3\. Suffering from serious uncontrolled other systemic diseases, including chest and abdominal surgery, heart attack (angina pectoris, myocardial infarction, malignant arrhythmia, etc.) and cerebrovascular disease (stroke) within 3 months, as well as kidney disease (AKI), cirrhosis, and any malignant tumor except lung cancer. 4\. Suffering from severe cognitive impairment. 5\. With active tuberculosis or are taking anti-tuberculosis treatment. 6\. Pregnancy or lactation. 7\. Previous lung surgery. 8\. Acute upper and lower respiratory system infection within 4 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| lung function | Lung function will be tested at the 1st year, the 2nd year and the 3rd year. | Patients' lung function will be tested to identify air flow decrease in the early COPD group and the control group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood samples | The 1st year and the 3rd year of follow-up | Collect venous blood to detect cytokines and other molecular. |
| CT | The 1st year and the 3rd year of follow-up | Both inspiration phase and expiration phase are required |
| Exhaled breath condensate | The 1st year and the 3rd year | Using commercially available exhaled breath condensate collection |
| Exhaled hydrogen sulfide and nitric oxide | The 1st year and the 3rd year | Using breath analyzer to detect real-time release |
| Pulmonary tissue | The 1st year patients are enrolled | Pulmonary tissue will be obtained from patients who are about to undergo resection, for example, COPD patients with lung cancer. |
Countries
China
Contacts
Primary ContactYahong Chen, PHD
Outcome results
None listed